DocCheck AG AI Stock Analysis
Want to see DE:AJ91 full AI Analyst Report?
DocCheck AG (AJ91) AI Stock Analysis
DocCheck AG
(XETRA:AJ91)
DocCheck AG scores in the mid-range. The dominant factor is mixed financial performance: a healthy, low-debt balance sheet is offset by a stagnant top line well below its 2021 peak, compressed margins, and a near-50% drop in free cash flow with weak earnings-to-cash conversion. Technicals are a further drag, with the price below all key moving averages and negative MACD, though oversold RSI and Stochastic readings suggest downside may be extended near term. The main support comes from valuation — a modest 10.4x P/E and a ~9.2% dividend yield — although the sustainability of that payout is questionable given thin free cash flow. Suitable mainly for income-oriented investors comfortable with limited growth visibility.
DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 51.25M
- Dividend Yield
- 9.90%
- Average Volume (3M)
- 379
- Price to Earnings (P/E)
- 11.0
- Beta (1Y)
- 0.44
- Revenue Growth
- 1.35%
- EPS Growth
- -20.52%
- Country
- Germany
- Employees
- 414
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
DocCheck AG Business Overview & Revenue Model
Company Description
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medic...
How the Company Makes Money
DocCheck AG primarily generates revenue by selling digital marketing, communication, and related online services to customers in the healthcare and life-sciences industry, using its healthcare-professional-focused online environment and audience acce...
DocCheck AG Financial Statement Overview
Summary
Mixed fundamentals. The balance sheet is solid (score 72): debt-to-equity has fallen to 0.10, equity has grown steadily to €41.6M, and solvency is strong. However, the income statement (score 42) shows revenue contracting ~36% from the 2021 peak to ~€55M with a -2.2% decline in 2025 and margins structurally below pandemic-era levels, despite net income recovering to €5.3M. Cash flow (score 45) is the weakest area: free cash flow fell ~50% to €2.6M with FCF/net income conversion of just 0.43. Profitable and safe, but growth and cash generation are deteriorating.
Income Statement
42NeutralBalance Sheet
72PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.65M | 55.32M | 53.79M | 53.41M | 60.90M | 85.92M |
| Gross Profit | 10.57M | 12.28M | 10.53M | 12.97M | 14.08M | 21.54M |
| EBITDA | 10.02M | 10.39M | 10.18M | 9.38M | 13.38M | 20.09M |
| Net Income | 4.66M | 5.33M | 5.28M | 2.27M | 6.29M | 11.40M |
Balance Sheet | ||||||
| Total Assets | 53.40M | 55.68M | 60.86M | 56.14M | 63.28M | 60.25M |
| Cash, Cash Equivalents and Short-Term Investments | 15.98M | 18.54M | 21.02M | 17.52M | 15.66M | 21.52M |
| Total Debt | 2.76M | 4.16M | 5.01M | 5.85M | 7.07M | 7.03M |
| Total Liabilities | 15.08M | 14.07M | 20.78M | 18.11M | 23.86M | 22.08M |
| Stockholders Equity | 38.32M | 41.61M | 40.08M | 37.33M | 38.57M | 37.31M |
Cash Flow | ||||||
| Free Cash Flow | 1.52M | 2.61M | 6.82M | 5.62M | -557.91K | 6.90M |
| Operating Cash Flow | 5.26M | 6.14M | 7.82M | 7.51M | 5.89M | 10.92M |
| Investing Cash Flow | -2.65M | -3.81M | -1.48M | -1.93M | -4.92M | -4.39M |
| Financing Cash Flow | -6.07M | -4.88M | -3.50M | -4.60M | -5.81M | -5.86M |
DocCheck AG Peers Comparison
Overall Rating
DE:ILM159Neutral
DE:AJ9156Neutral
DE:M3V55Neutral
DE:COP53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | EUR 269.85M | 24.05 | 2.16% | ― | 8.41% | -61.58% | |
| 56Neutral | EUR 51.25M | 10.98 | 11.67% | 9.90% | 1.35% | -20.52% | |
| 55Neutral | EUR 38.95M | 28.16 | 7.77% | 4.44% | -6.92% | -67.82% | |
| 53Neutral | EUR 1.45B | 43.42 | 4.19% | 1.80% | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:AJ91 | DocCheck AG | 10.10 | -0.28 | -2.66% | |
| DE:COP | CompuGroup Medical | 27.45 | 4.13 | 17.71% | |
| DE:M3V | MeVis Medical Solutions | 21.40 | -2.50 | -10.46% | |
| DE:ILM1 | Medios AG | 10.58 | -3.20 | -23.22% | |
| DE:MDQ | MediNavi AG | 3.80 | -0.20 | -5.00% | |
| DE:5NB | Novetum AG | 42.00 | 13.40 | 46.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026
